Heidi Øyen Flemmen

  • Consultant of neurology; MD

Heidi Øyen Flemmen has a medical degree from University of Bergen (2000) and is a specialist in neurology from 2014. She works as a senior consultant at the Department of Neurology, Telemark Hosptial, with a special interest in MS patients.

As of August 2016 she has been working 50 % as a PhD student within this project and 50 % as a clinician at Department of Neurology in Telemark Hospital.  

Project title: "Socioeconomic factors as predictors for disease susceptibility and disease progression in Multiple sclerosis."

Research project: Heidi Øyen Flemmen is doing her PhD project on multiple sclerosis and socioeconomic factors. The project title is socioeconomic factors as predictors for disease susceptibility and disease progression in Multiple sclerosis. The aim of this study is to evaluate factors predicting disease susceptibility, progression and access to treatment in a complete geographically well-defined cohort of all MS patients in Oslo, Buskerud and Telemark

Main supervisor: Elisabeth Gulowsen Celius (MD, PhD.)
Co-supervisors: Pål Berg-Hansen (MD, PhD) and Kristian Heldal (MD, PhD, senior consultant, Telemark Hospital)

Methodology and interests:

  • Epidemiology
  • Clinical research and clinical trials in MS
  • Environmental factors associated with MS
  • Socioeconomic factors as predictors of health
 

Publications 2024

Frederiksen JL, Massacesi L, Nielsen HH, Rini A, Baldi E, Mirabella M, Antonella FFM, Lus G, Paolicelli D, Kant M, Salemi G, Aguglia U, Comi C, De Riz M, Barcella V, Flemmen HØ, Protti A, Farbu E, van Exel J, Torkildsen Ø (2024)
Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence study
Mult Scler Relat Disord, 93, 106214 (in press)
DOI 10.1016/j.msard.2024.106214, PubMed 39642455

Novy C, Busk ØL, Tysnes OB, Landa SS, Aanjesen TN, Alstadhaug KB, Bjerknes TL, Bjørnå IK, Bråthen G, Dahl E, Demic N, Fahlström M, Flemmen HØ, Hallerstig E, HogenEsch I, Kampman MT, Kleveland G, Kvernmo HB, Ljøstad U, Maniaol A, Morsund AH, Nakken O, Olsen CG, Schlüter K, Utvik MS et al. (2024)
Repeat expansions in AR, ATXN1, ATXN2 and HTT in Norwegian patients diagnosed with amyotrophic lateral sclerosis
Brain Commun, 6 (2), fcae087
DOI 10.1093/braincomms/fcae087, PubMed 38585669

Olsen CG, Malmberg VN, Fahlström M, Alstadhaug KB, Bjørnå IK, Braathen GJ, Bråthen G, Demic N, Hallerstig E, Hogenesch I, Horn MA, Kampman MT, Kleveland G, Ljøstad U, Maniaol A, Morsund ÅH, Nakken O, Schlüter K, Schuler S, Seim E, Flemmen HØ, Tysnes OB, Holmøy T, Høyer H (2024)
Amyotrophic lateral sclerosis caused by the C9orf72 expansion in Norway - prevalence, ancestry, clinical characteristics and sociodemographic status
Amyotroph Lateral Scler Frontotemporal Degener, 1-9 (in press)
DOI 10.1080/21678421.2024.2405118, PubMed 39316038

Simonsen CS, Flemmen HØ, Broch L, Myklebust H, Berg-Hansen P, Brunborg C, Celius EG (2024)
The influence of menopause on multiple sclerosis
Eur J Neurol, 32 (1), e16566
DOI 10.1111/ene.16566, PubMed 39601490

Publications 2023

Broch L, Flemmen HØ, Simonsen CS, Berg-Hansen P, Ormstad H, Brunborg C, Celius EG (2023)
"No association between disease modifying treatment and fatigue in multiple sclerosis"
Mult Scler Relat Disord, 79, 104993
DOI 10.1016/j.msard.2023.104993, PubMed 37708819

Publications 2022

Broch L, Flemmen HØ, Simonsen CS, Berg-Hansen P, Ormstad H, Brunborg C, Celius EG (2022)
Fatigue in multiple sclerosis is associated with socioeconomic factors
Mult Scler Relat Disord, 64, 103955
DOI 10.1016/j.msard.2022.103955, PubMed 35753177

Flemmen HØ, Simonsen CS, Broch L, Brunborg C, Berg-Hansen P, Moen SM, Kersten H, Celius EG (2022)
The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort
Mult Scler Relat Disord, 61, 103759
DOI 10.1016/j.msard.2022.103759, PubMed 35358792

Olsen CG, Busk ØL, Aanjesen TN, Alstadhaug KB, Bjørnå IK, Braathen GJ, Breivik KL, Demic N, Flemmen HØ, Hallerstig E, HogenEsch I, Holla ØL, Jøntvedt AB, Kampman MT, Kleveland G, Kvernmo HB, Ljøstad U, Maniaol A, Morsund ÅH, Nakken O, Novy C, Rekand T, Schlüter K, Schüler S, Tveten K et al. (2022)
Genetic Epidemiology of Amyotrophic Lateral Sclerosis in Norway: A 2-Year Population-Based Study
Neuroepidemiology, 56 (4), 271-282
DOI 10.1159/000525091, PubMed 35576897

Simonsen CS, Flemmen HØ, Broch L, Brekke K, Brunborg C, Berg-Hansen P, Celius EG (2022)
Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population
Front Neurol, 13, 1034056
DOI 10.3389/fneur.2022.1034056, PubMed 36452173

Solheim AM, Lorentzen ÅR, Dahlberg AO, Flemmen HØ, Brune S, Forselv KJN, Pripp AH, Bø MH, Eikeland R, Reiso H, Mygland Å, Ljøstad U (2022)
Six versus 2 weeks treatment with doxycycline in European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blinded, randomised and placebo-controlled trial
J Neurol Neurosurg Psychiatry, 93 (11), 1222-8 (in press)
DOI 10.1136/jnnp-2022-329724, PubMed 35896378

Publications 2021

Broch L, Simonsen CS, Flemmen HØ, Berg-Hansen P, Skardhamar Å, Ormstad H, Celius EG (2021)
High prevalence of fatigue in contemporary patients with multiple sclerosis
Mult Scler J Exp Transl Clin, 7 (1), 2055217321999826
DOI 10.1177/2055217321999826, PubMed 33796331

Eid K, Torkildsen ØF, Aarseth J, Flemmen HØ, Holmøy T, Lorentzen ÅR, Myhr KM, Riise T, Simonsen C, Torkildsen CF, Wergeland S, Willumsen JS, Øksendal N, Gilhus NE, Bjørk MH (2021)
Perinatal Depression and Anxiety in Women With Multiple Sclerosis: A Population-Based Cohort Study
Neurology, 96 (23), e2789-e2800
DOI 10.1212/WNL.0000000000012062, PubMed 33883236

Flemmen HØ, Simonsen CS, Broch L, Brunborg C, Berg-Hansen P, Moen SM, Kersten H, Celius EG (2021)
Maternal education has significant influence on progression in multiple sclerosis
Mult Scler Relat Disord, 53, 103052
DOI 10.1016/j.msard.2021.103052, PubMed 34111658

Simonsen CS, Flemmen HØ, Broch L, Brunborg C, Berg-Hansen P, Moen SM, Celius EG (2021)
Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry
Front Neurol, 12, 693017
DOI 10.3389/fneur.2021.693017, PubMed 34220694

Simonsen CS, Flemmen HØ, Broch L, Brunborg C, Berg-Hansen P, Moen SM, Celius EG (2021)
No significant differences in absenteeism or academic achievements in a Norwegian multiple sclerosis case control study
Mult Scler Relat Disord, 54, 103141
DOI 10.1016/j.msard.2021.103141, PubMed 34273610

Publications 2020

Eikeland R, Ljøstad U, Helgeland G, Sand G, Flemmen HØ, Bø MH, Nordaa L, Owe JF, Mygland Å, Lorentzen ÅR (2020)
Patient-reported outcome after treatment for definite Lyme neuroborreliosis
Brain Behav, 10 (4), e01595
DOI 10.1002/brb3.1595, PubMed 32153118

Flemmen HØ, Simonsen CS, Berg-Hansen P, Moen SM, Kersten H, Heldal K, Celius EG (2020)
Prevalence of multiple sclerosis in rural and urban districts in Telemark county, Norway
Mult Scler Relat Disord, 45, 102352
DOI 10.1016/j.msard.2020.102352, PubMed 32707528

Simonsen CS, Flemmen HØ, Broch L, Brunborg C, Berg-Hansen P, Moen SM, Celius EG (2020)
The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression
J Neurol, 268 (4), 1330-1341
DOI 10.1007/s00415-020-10279-7, PubMed 33090270

Simonsen CS, Flemmen HØ, Lauritzen T, Berg-Hansen P, Moen SM, Celius EG (2020)
The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis
Mult Scler J Exp Transl Clin, 6 (1), 2055217319901291
DOI 10.1177/2055217319901291, PubMed 32030196

Publications 2017

Lorentzen ÅR, Forselv KJN, Helgeland G, Salvesen RE, Sand G, Flemmen HØ, Bø MH, Nordaa L, Roos AK, Jim MW, Owe JF, Nyquist KB, Schüler S, Eikeland R, Mygland Å, Ljøstad U (2017)
Lyme neuroborreliosis: do we treat according to guidelines?
J Neurol, 264 (7), 1506-1510
DOI 10.1007/s00415-017-8559-z, PubMed 28676925

Scroll to top